189 related articles for article (PubMed ID: 23036071)
1. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment.
Grimmer T; Wutz C; Drzezga A; Förster S; Förstl H; Ortner M; Perneczky R; Kurz A
Curr Alzheimer Res; 2013 Jan; 10(1):82-5. PubMed ID: 23036071
[TBL] [Abstract][Full Text] [Related]
2. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
3. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
[TBL] [Abstract][Full Text] [Related]
5. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected].
Ma Y; Zhang S; Li J; Zheng DM; Guo Y; Feng J; Ren WD
Medicine (Baltimore); 2014 Dec; 93(27):e150. PubMed ID: 25501055
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and acceptance of simultaneous amyloid PET/MRI.
Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
[TBL] [Abstract][Full Text] [Related]
8. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia.
Gomperts SN; Locascio JJ; Rentz D; Santarlasci A; Marquie M; Johnson KA; Growdon JH
Neurology; 2013 Jan; 80(1):85-91. PubMed ID: 23243071
[TBL] [Abstract][Full Text] [Related]
9. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
[TBL] [Abstract][Full Text] [Related]
10. Amyloid deposition and CBF patterns predict conversion of mild cognitive impairment to dementia.
Kikukawa T; Abe T; Ataka S; Saito H; Hasegawa I; Mino T; Takeuchi J; Kawabe J; Wada Y; Watanabe Y; Itoh Y
Neurol Sci; 2018 Sep; 39(9):1597-1602. PubMed ID: 29936556
[TBL] [Abstract][Full Text] [Related]
11. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
12. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
[TBL] [Abstract][Full Text] [Related]
13. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
[TBL] [Abstract][Full Text] [Related]
14. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
15. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
[TBL] [Abstract][Full Text] [Related]
16. Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting: A Visual and Semiquantitative Analysis.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Sánchez-Juan P; Carril JM
Clin Nucl Med; 2016 Jan; 41(1):e18-23. PubMed ID: 26284764
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.
Elias-Sonnenschein LS; Viechtbauer W; Ramakers IH; Verhey FR; Visser PJ
J Neurol Neurosurg Psychiatry; 2011 Oct; 82(10):1149-56. PubMed ID: 21493755
[TBL] [Abstract][Full Text] [Related]
18. The correlation of neuropsychological evaluation with 11C-PiB and 18F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease.
Park SY; Byun BH; Kim BI; Lim SM; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH
Medicine (Baltimore); 2020 Apr; 99(16):e19620. PubMed ID: 32311931
[TBL] [Abstract][Full Text] [Related]
19. Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI.
Kemppainen NM; Scheinin NM; Koivunen J; Johansson J; Toivonen JT; Någren K; Rokka J; Karrasch M; Parkkola R; Rinne JO
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):283-9. PubMed ID: 24072346
[TBL] [Abstract][Full Text] [Related]
20. Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
Koivunen J; Karrasch M; Scheinin NM; Aalto S; Vahlberg T; Någren K; Helin S; Viitanen M; Rinne JO
Dement Geriatr Cogn Disord; 2012; 34(1):31-7. PubMed ID: 22868352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
